103
Participants
Start Date
March 31, 2010
Primary Completion Date
July 31, 2013
Study Completion Date
March 31, 2014
inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone
"Day 1:~Rituximab at 375 mg/m2 Cyclophosphamide at 375 mg/m2 (cohort 1), 550mg/m2 (cohort 2), 750 mg/m2 (cohort 3, 4) Vincristine at 1.4 mg/m2 (max 2 mg)~Day 2 Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2, 3), 1.3 mg/m2 (cohort 4)~Days 1-5:~Prednisone at 40 mg/m2~Each cycle is 3 weeks, with a maximum of 6 cycles total."
inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone
"Day 1:~Rituximab at 375 mg/m2 Gemcitabine at 500 mg/m2 (cohort 1, 2b, 3b), 1000mg/m2 (cohort 2a, 3a, 4, 5) Cisplatin at 37.5 mg/m2 (cohort 1, 2a), 50mg/m2 (cohort 2b, 3a), 75mg/m2 (cohort 3b, 4, 5)~Day 2:~Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2a, 2b, 3a, 3b, 4), 1.3mg/m2 (cohort 5)~Days 1-4:~Dexamethasone at 40 mg~Each cycle is 3 weeks, with a maximum of 6 cycles total."
UZ Gasthuisberg, Leuven
UZ Gent, Ghent
Davis Cancer Pavillion and Shands Medical Plaza, Gainesville
Shands Cancer Hospital At The University Of Florida, Gainesville
Shands Hospital at the University of Florida, Gainesville
Centre Hospitalier Lyon Sud - Service d'Hematologie, Pierre-Bénite
Hopital Saint-Louis -Universite Paris VII, Paris
Hospital Saint-Louis - Service d'Hemato-Oncologie, Paris
Northwest Medical Specialties, PLLC, Federal Way
Northwest Medical Specialties, PLLC, Gig Harbor
Rainier Physicians, PC, Puyallup
Northwest Medical Specialties PLLC, Tacoma
Northwest Medical Specialties, PLLC, Lakewood
Singapore General Hospital, Singapore
Fox Chase Cancer Center, Philadelphia
The University of Texas MD Anderson Cancer Center, Houston
Cross Cancer Institute, Edmonton
Queen Elizabeth Health Sciences Centre, Halifax
Princess Margaret Cancer Centre, Toronto
Prince of Wales Hospital, Hong Kong
Nagoya Daini Red Cross Hospital, Nagoya
National Cancer Center Hospital, Chuo-ku
Cancer Institute Hospital, Japanese Foundation For Cancer Research, Koto-Ku
Samsung Medical Center, Seoul
Nuffield Hospital, Eastleigh
Spire Southampton Hospital, Southampton
Cancer Sciences Division, Somers Cancer Research Building, Southampton
Guy's and St Thomas' NHS Foundation Trust, London
Lead Sponsor
Collaborators (1)
UCB Pharma
INDUSTRY
Pfizer
INDUSTRY